Abstract: Objective To evaluate the efficacy and safety of Abriaterone acetate on the patients with castration-resistant prostate cancer(CRPC). Methods A total of 58 CRPC patients (median age: 68 years old) received two cycles of Abriaterone acetate. RECIST was used to assess the efficacy of the treatment and NCICTC-AE version 3.0 was used to describe adverse events; Kaplan-meier analysis was used for analyzing overall survival(OS). Results Five cases were not subjected to evaluate. Among 53 patients with castrationresistant prostate cancer, ORR was 18.87% (10 cases) and disease contral rate (DCR) was 62.26%(33 cases); The median OS was (15.0±1.2) month; The PSA levels were decreased in 53 patients, and decreased more than 50% in 28 patients. The median PSA level was 78 ng/ml (18~1 776 ng/ml) and 37 ng/ml (9~320 ng/ml) respectively before and after treatment, with significant difference(P﹤0.05). The principal drug related adverse events were grade Ⅰ - Ⅱ. Conclusion With minor toxicity, the combination of Abriaterone acetate plus prednisone has a certain effect on castration-resistant prostate cancer patients.